IntelGenx Technologies Corp. Forms 3, 4 and 5: Corporate Securities (Bonds and Notes)
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows, 13 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-04-19: Reporting owner ATAI Life Sciences AG | ATAI Life Sciences N.V.; Form 4; Security Convertible Notes; Transaction J Other acquisition or disposition (describe transaction).
- 2024-03-08: Reporting owner ATAI Life Sciences N.V. | ATAI Life Sciences AG; Form 4; Security Convertible Notes; Transaction J Other acquisition or disposition (describe transaction).
- 2023-11-28: Reporting owner ATAI Life Sciences N.V. | ATAI Life Sciences AG; Form 4; Security Convertible Promissory Note; Transaction P Open market or private purchase of non-derivative or derivative security.
- 2023-10-06: Reporting owner ATAI Life Sciences N.V. | ATAI Life Sciences AG; Form 4; Security Convertible Notes; Transaction J Other acquisition or disposition (describe transaction).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-04-19 | ATAI Life Sciences AG | ATAI Life Sciences N.V. 10% Owner | 10% Owner | 4 | Convertible Notes Derivative · Indirect · By ATAI Life Sciences AG | J Other acquisition or disposition (describe transaction) | $0.19 exercise price | 2024-05-03 | ||
| 2024-03-08 | ATAI Life Sciences N.V. | ATAI Life Sciences AG 10% Owner | 10% Owner | 4 | Convertible Notes Derivative · Indirect · By ATAI Life Sciences AG | J Other acquisition or disposition (describe transaction) | +1,000,000 9,500,000 owned after | $0.19 exercise price | 2024-03-12 | |
| 2023-11-28 | ATAI Life Sciences N.V. | ATAI Life Sciences AG 10% Owner | 10% Owner | 4 | Convertible Promissory Note Derivative · Indirect · By ATAI Life Sciences AG | P Open market or private purchase of non-derivative or derivative security | +750,000 2,970,000 owned after | $0.19 exercise price | 2024-03-12 | |
| 2023-10-06 | ATAI Life Sciences N.V. | ATAI Life Sciences AG 10% Owner | 10% Owner | 4 | Convertible Notes Derivative · Indirect · By ATAI Life Sciences AG | J Other acquisition or disposition (describe transaction) | +8,500,000 8,500,000 owned after | $0.19 exercise price | 2024-03-12 | |
| 2023-08-31 | ATAI Life Sciences AG | ATAI Life Sciences N.V. 10% Owner | 10% Owner | 4 | Convertible Promissory Note Derivative · Indirect · By ATAI Life Sciences AG | P Open market or private purchase of non-derivative or derivative security | +11,999,100 11,999,100 owned after | $0.19 exercise price | 2023-09-05 | |
| 2022-07-07 | Godin Andre Officer (President and CFO) | 4 | 8% 2017 Convertible Debenture Derivative · Direct | J Other acquisition or disposition (describe transaction) | −20,000 0 owned after | $0.22 exercise price | 2022-07-08 | |
| 2022-07-07 | Zerbe Ingrid Officer (Corporate Secretary) | 4 | 8% 2017 Convertible Debenture Derivative · Direct | J Other acquisition or disposition (describe transaction) | −100,000 0 owned after | $0.22 exercise price | 2022-07-08 | |
| 2020-07-06 holding as of filing | Zerbe Ingrid Officer (Corporate Secretary) | 4 | 2017 8% Convertible Debentures Derivative · Direct | Holding | 100,000 owned after | $0.37 exercise price | 2020-07-06 | |
| 2020-07-06 holding as of filing | Godin Andre Officer (President and CFO) | 4 | 2017 8% Convertible Debentures Derivative · Direct | Holding | 20,000 owned after | $0.37 exercise price | 2020-07-06 | |
| 2018-05-08 | Godin Andre Officer (EVP and CFO) | 4/A | 6% Convertible Debenture Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +12,500 12,500 owned after | $0.80 | 2018-05-11 | |
| 2018-05-08 | Godin Andre Officer (EVP and CFO) | 4 | 6% Convertible Debenture Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +12,500 12,500 owned after | $0.80 | 2018-05-10 | |
| 2017-07-12 | Godin Andre Officer (EVP & CFO) | 4 | 8% Conv. Debentures Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +20,000 20,000 owned after | $0.78 | 2017-07-14 | |
| 2017-07-12 | Zerbe Ingrid Officer (Corporate Secretary) | 4 | 8% Conv. Debentures Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +100,000 100,000 owned after | $0.78 | 2017-07-14 |